Eli Lilly | LLY - Interest Expense On Debt


Eli Lilly reported $114.7M in Interest Expense on Debt for its fiscal quarter ending in September of 2025.





Interest Expense On Debt Change Date
AbbVie USD 645M 69M Mar/2026
Abbott USD 68M 26M Mar/2026
ALKERMES USD 20.89M 8.62M Mar/2026
Amgen USD 657M 4M Mar/2026
AstraZeneca USD 484M 181M Dec/2025
Baxter International USD 58M 14M Sep/2025
Biogen USD 72.6M 12.6M Jun/2025
Bristol-Myers Squibb USD 411M 21M Mar/2026
Coherus Biosciences USD 2.25M 76K Dec/2025
Drreddys Laboratories INR 1.06B 113M Mar/2026
Eli Lilly USD 114.7M 134.3M Sep/2025
Gilead Sciences USD 240M 15M Mar/2026
GlaxoSmithKline GBP 167M 21M Mar/2026
Glaxosmithkline GBP 192.73M 14.79M Mar/2026
J&J USD 43M 25M Mar/2026
Medtronic USD 176M 5M Mar/2026
Merck USD 479M 67M Mar/2026
Neurocrine Biosciences USD 1.1M 0 Mar/2024
Novartis USD 343M 39M Mar/2026
Novartis USD 281M 8M Sep/2025
Novo Nordisk DKK 1.53B 3.43B Sep/2025
Perrigo USD 7.98B 7.94B Mar/2026
Pfizer USD 671M 40M Mar/2026
Phibro Animal Health USD 11.91M 191K Dec/2025
Prestige Brands USD 10.67M 636K Dec/2025
Regeneron Pharmaceuticals USD 12.9M 700K Mar/2026
Roche Holding CHF 304M 7.5M Jun/2025
Sanofi EUR 178M 203M Mar/2026
Sanofi EUR -25M 99.78M Dec/2025
United Therapeutics USD 3.1M 100K Dec/2025
Zoetis USD 62M 5M Mar/2026